Rheumatoid arthritis is a systemic autoimmune rheumatic disorder of unknown etiology.
It is the most common form of inflammatory arthritis.
Patient usually complains of joint pain and/or swelling with morning stiffness that lasts for more than an hour.
Goals of treatment are clinical & radiological remission of disease and to reduce functional limitations & permanent joint damage.
Rheumatoid arthritis remission may be sustained following abatacept tapering, particularly in patients with shorter disease duration and long sustained remission, according to a study. Furthermore, ultrasound is a useful tool to identify disease activity flare.
Treatment with tumour necrosis factor inhibitor (TNFi) does not carry a heightened risk of cancer recurrence in patients with rheumatoid arthritis (RA) and a history of cancer, as shown in a recent study.
Biologics therapy can be successfully tapered in most rheumatoid arthritis patients who have achieved sustained remission, especially in subgroups of male patients, those with exposure to a maximum of one previous biological disease-modifying antirheumatic drug, and those with low baseline inflammation or damage score, according to 2-year data from a recent study.
Using a multimodal intervention may improve uptake of influenza vaccination in patients with rheumatoid arthritis (RA), reports a study, adding that some subgroups may need a more potent approach for equivalent efficacy.
Tuberculosis (TB) is an important adverse event associated with the use of biologics, especially antitumour necrosis factor, in the management of autoimmune inflammatory rheumatic diseases, according to a study. Prophylaxis can effectively reduce the risk in patients testing positive for latent TB at screening.
Rheumatoid arthritis (RA) disease control appears to be better with continued 4-mg baricitinib treatment than with a 2-mg dose step-down approach, according to substudy data from the ongoing phase III RA-BEYOND extension trial.
Initiation of abatacept (ABA) vs tumour necrosis factor inhibitors (TNFi) leads to a 20-percent reduction in risk of cardiovascular disease (CVD) in a large cohort of insured patients with rheumatoid arthritis (RA), a US study has shown.
Long-term treatment with subcutaneous (SC) abatacept (ABA) is safe, tolerable and effective in patients with rheumatoid arthritis (RA) who are refractory to methotrexate (MTX), according to 5-year data from a recent study.
Selective inhibition of Janus kinase 1 with upadacitinib shows promise in the treatment of rheumatoid arthritis patients with inadequate response to biologic or conventional synthetic disease-modifying antirheumatic drugs, according to data from two phase III trials.
The types of bariatric surgery differentially affect the risk of developing acute pancreatitis postoperatively, such that the risk is greater in patients who undergo vertical sleeve gastrectomy vs Roux-en-Y gastric bypass surgery, according to a study. Risk factors include younger age and presence of gallstones.
An adjuvant trastuzumab treatment course shortened to 9 weeks has failed to demonstrate noninferiority to the standard 1-year course in terms of disease-free survival in breast cancer patients, although the shortened course confers benefits for the risk of severe cardiac toxicity, according to the results of the phase III randomized Short-HER study.